Effect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial
Zarif Yeganeh M, Vakili M, Shahriari-Ahmadi A, Nojomi M
Iranian journal of public health · 6 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2016-01-01 · Iran J Public Health · vol. 45 · issue 1 · pp. 54–62
- Publisher
- National Institutes of Health
- Cited
- 14 citations · more than 79% of similar papers · 1.4× the field average
- References
- 43 works
- Access
- Open access (repository copy)
- Research areas
- Chemotherapy-induced organ toxicity mitigation · Magnesium in Health and Disease · Silymarin and Mushroom Poisoning
- Keywords
- Hypomagnesemia, Medicine, Cisplatin, Randomized controlled trial, Chemotherapy, Internal medicine, Gastroenterology, Cancer, Magnesium, Chemistry
4 authors
From IR
- Maryam Zarif YeganehRasool Akram Hospital
- Masoud VakiliRasool Akram Hospital
- Ali Shahriari-AhmadiRasool Akram Hospital
- Marzieh Molavi NojomiIran University of Medical Sciences
Abstract
Background
Hypomagnesaemia is one of the main side effects of cisplatin-based chemotherapy regimens in cancer patients. The aim of the current investigation was to evaluate the effect of oral magnesium oxide (MgO) supplementation on cisplatin-induced hypomagnesemia.
Methods
This parallel-randomized controlled, open label trial was conducted in a hospital of Iran University of Medical Sciences in Tehran between December 2009 and May 2011. Participants were 69 adult patients with newly diagnosed non- leukemia neoplasms candidate for starting cisplatin-based chemotherapy. Oral MgO supplement according to cisplatin dose (500 mg MgO per 50 mg/m(2) of cisplatin) as 2-3 divided daily doses was started after completion of each chemotherapy cycle and continued to the next cycle for the intervention group. Patients in the control group did not receive any supplementation. Serum magnesium (Mg) was measured before each chemotherapy cycle. The main outcome was measuring serum Mg change and hypomagnesaemia rate during chemotherapy treatment.
Results
Sixty-two participants (31 intervention- 31 controls) enrolled into the study. Serum Mg levels showed significant difference between the two groups (P=0.01). There was a significant decrease in serum Mg of the control group (P=0.001). At the end of follow-up period prevalence of hypomagnesaemia in the intervention group was 10.7% versus 23.1% in the control group.
Conclusion
Continuously oral supplementation with MgO according to cisplatin dose (500 mg MgO per 50 mg/m(2) cisplatin) as 2-3 divided daily doses at rest days between chemotherapy cycles reduces the decline in serum Mg levels and also the prevalence of hypomagnesaemia in cancer patients.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.